📋 Tender Overview
The contract involves entering into a non-exclusive discount agreement for pharmaceuticals containing the active ingredient Bexarotene (ATC code: L01XF03) for the period from November 1, 2026, to October 31, 2028, with the possibility of contract conclusion at any time during the term (open-house model). The agreements are intended to bridge the gap between the start of generic competition (patent expiration) and the awarding of exclusive contracts. Bexarotene